HR Execs on the Move

QUATRx Pharmaceuticals Company

www.quatrx.com

 
QUATRx Pharmaceuticals Company is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.quatrx.com
  • 777 E Eisenhower Pkwy
    Ann Arbor, MI USA 48108
  • Phone: 734.913.9900

Executives

Name Title Contact Details

Similar Companies

Logical Therapeutics

Logical Therapeutics is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syngenta Biotechnology Inc

Syngenta Biotechnology Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pivotal Therapeutics

Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF; CSE:PVO), specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics` lead product VASCAZEN is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada.

La Jolla Bioengineering Institute

La Jolla Bioengineering Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.